Alaunos Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
TCRT Nasdaq 8731 https://alaunos.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alaunos Therapeutics Inc

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting - May 25th, 2023 9:00 pm
Alaunos Therapeutics Reports First Quarter 2023 Financial Results - May 10th, 2023 11:00 am
Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023 - May 3rd, 2023 12:30 pm
Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting - Apr 26th, 2023 4:30 pm
Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors - Mar 30th, 2023 11:00 am
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April - Mar 29th, 2023 9:30 pm
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results - Mar 7th, 2023 12:00 pm
Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023 - Feb 28th, 2023 9:01 pm
Alaunos Therapeutics, Inc.'s (NASDAQ:TCRT) largest shareholders are individual investors with 58% ownership, institutions own 22% - Feb 17th, 2023 10:47 am
Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023 - Jan 9th, 2023 1:30 pm
Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock - Nov 29th, 2022 2:01 pm
Alaunos Therapeutics Announces Proposed Public Offering of Common Stock - Nov 28th, 2022 9:01 pm
Alaunos Therapeutics Reports Third Quarter 2022 Financial Results - Nov 14th, 2022 12:00 pm
Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022 - Nov 8th, 2022 1:30 pm
Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting - Nov 7th, 2022 1:00 pm
Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference - Sep 21st, 2022 12:30 pm
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September - Sep 7th, 2022 12:30 pm
Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy - Sep 6th, 2022 12:00 pm
Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference - Aug 24th, 2022 7:00 pm
Alaunos Therapeutics Reports Second Quarter 2022 Financial Results - Aug 15th, 2022 11:00 am